Balance Sheet Components - Assets and Liabilities Held For Sale (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue of biosimilars portfolio		$ 169.1
Liabilities held for sale		277.7	$ 0.0
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Biocon Biologics | Biosimilars Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net		136.1
Inventories		122.4
Prepaid expenses and other current assets		12.5
Intangible assets, net		7.5
Goodwill		953.0
Other assets		105.6
Accounts payable		95.4
Accounts payable		$ 182.3
Disposal Group, Held-for-sale or Disposed of by Sale, Not Discontinued Operations | Scenario, Forecast | Biocon Biologics | Biosimilars Portfolio
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Upfront payment subject to certain adjustments	$ 2,000.0
Percent ownership after transaction	12.90%
Additional cash payments to be received	$ 335.0
Term of transition services agreement	2 years